MORE INFORMATION HERE 18:15 – 18:30 The real-world burden of diabetes and hypoglycemia: Results from the iNPHORM study Stewart Harris (CAN)Alexandria Ratzki-Leewing (CAN) 18:30 –
09:15 – 09:35 How and why to identify high-risk patients: lessons from the clinic Elmar Jaeckel (GER)Lise Lotte Gluud (DNK) 09:35 – 09:45 The future
Outcomes of an EU Advisory Board on digital therapeutics and a look at OneTouch Reveal remote monitoring usage in real life 18:15 – 18:20 Introductions
Presenter: Andreas Pfützner (GER) Glucose monitoring interferences when using BGM/CGM. 30.09.2021 09:15 – 09:45 Meet the Expert
Speaker: Michael Nauck (GER) 09:35 – 09:45 Michael Nauck talks about the incretin journey: from past research, to current understandings, to where the field could
20:00 – 20:05 Welcome and Introductions Bo Ahrén (SWE) 20:05 – 20:40 Health risks associated with elevated postprandial glucose or increased glycaemic variability Louis Monnier
Faculty: David Cherney (CAN), Kim Connelly (CAN), Sam Dagogo-Jack (USA) 18:15 – 18:20 Opening Remarks Sam Dagogo-Jack (USA) 18:20 – 18:43 Cross-talk between the Heart,
Chair: Cecilia Low Wang (USA)Co-Chair: Mark Nehler (USA) 18:15 – 18:18 Introduction to faculty and program Cecilia Low Wang (USA)Mark Nehler (USA) 18:18 – 18:19
Speaker: Javed Butler (USA) The content for empagliflozin contained in this virtual session is intended for delegates from countries regulated by the European Medicines Agency (EMA),
Speaker:Paola Fioretto (ITA) 30.09.2021 18:05 – 18:15 Moscow Hall
